- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
- Interventions
- SHY-ONC6
- Drug
- Lead sponsor
- SHY Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Houston, Texas • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,273
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 665
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib, Placebo, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- 177Lu-PSMA-617
- Drug
- Lead sponsor
- Endocyte
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Abiraterone acetate, Prednisone, Placebo
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 982 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more
- Conditions
- NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets, MCLA-128
- Drug · Biological
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-101556143
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Lafayette, Louisiana • Plymouth, Massachusetts • Syracuse, New York + 1 more
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
- Interventions
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Drug · Diagnostic Test
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 16
- States / cities
- Duarte, California • Santa Monica, California • Stanford, California + 11 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- DCVAC/PCa, Placebo
- Biological
- Lead sponsor
- SOTIO a.s.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
- Conditions
- Prostate Cancer, Renal Cancer
- Interventions
- [68Ga]P16-093
- Drug
- Lead sponsor
- Five Eleven Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer Metastatic
- Interventions
- FOR46
- Drug
- Lead sponsor
- Fortis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, EPI-7386 with Enzalutamide
- Drug
- Lead sponsor
- ESSA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Interventions
- Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Male only
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- abiraterone acetate, dietary intervention, pharmacological study, questionnaire administration, laboratory biomarker analysis
- Drug · Dietary Supplement · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- REGN5678, Cemiplimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Interventions
- Navarixin, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Baltimore, Maryland + 2 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- BAY2315497 Injection, Darolutamide(BAY1841788)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- New Orleans, Louisiana • Omaha, Nebraska • New York, New York
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
- Drug · Radiation
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- [177Lu]Ludotadipep 3.7 GBq
- Drug
- Lead sponsor
- FutureChem
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Glioma, Malignant
- Interventions
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection
- Drug · Procedure
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- NMS-03305293
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Orteronel, Placebo, Prednisone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Duarte, California + 45 more